DE60019774T2 - Bioadhäsive nanopartikelformulierungen mit kationischen oberflächenstabilisatoren - Google Patents

Bioadhäsive nanopartikelformulierungen mit kationischen oberflächenstabilisatoren Download PDF

Info

Publication number
DE60019774T2
DE60019774T2 DE60019774T DE60019774T DE60019774T2 DE 60019774 T2 DE60019774 T2 DE 60019774T2 DE 60019774 T DE60019774 T DE 60019774T DE 60019774 T DE60019774 T DE 60019774T DE 60019774 T2 DE60019774 T2 DE 60019774T2
Authority
DE
Germany
Prior art keywords
less
nanoparticulate
drug
composition
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60019774T
Other languages
German (de)
English (en)
Other versions
DE60019774D1 (de
Inventor
William H. Bosch
R. Eugene COOPER
L. Simon MCGURK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perrigo Pharma International DAC
Original Assignee
Elan Pharma International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma International Ltd filed Critical Elan Pharma International Ltd
Application granted granted Critical
Publication of DE60019774D1 publication Critical patent/DE60019774D1/de
Publication of DE60019774T2 publication Critical patent/DE60019774T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/12—Powders or granules
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/24—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing ingredients to enhance the sticking of the active ingredients
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/30—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241—Containing particulates characterized by their shape and/or structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A61K8/416—Quaternary ammonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/731—Cellulose; Quaternized cellulose derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/817—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)
    • A61K8/8182—Copolymers of vinyl-pyrrolidones. Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/60—Particulates further characterized by their structure or composition
    • A61K2800/61—Surface treated
    • A61K2800/612—By organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/60—Particulates further characterized by their structure or composition
    • A61K2800/61—Surface treated
    • A61K2800/614—By macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dentistry (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fertilizers (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Jellies, Jams, And Syrups (AREA)
DE60019774T 1999-10-08 2000-10-05 Bioadhäsive nanopartikelformulierungen mit kationischen oberflächenstabilisatoren Expired - Lifetime DE60019774T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/414,159 US6428814B1 (en) 1999-10-08 1999-10-08 Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US414159 1999-10-08
PCT/US2000/027434 WO2001026635A2 (en) 1999-10-08 2000-10-05 Bioadhesive nanoparticulate compositions having cationic surface stabilizers

Publications (2)

Publication Number Publication Date
DE60019774D1 DE60019774D1 (de) 2005-06-02
DE60019774T2 true DE60019774T2 (de) 2006-03-09

Family

ID=23640205

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60019774T Expired - Lifetime DE60019774T2 (de) 1999-10-08 2000-10-05 Bioadhäsive nanopartikelformulierungen mit kationischen oberflächenstabilisatoren

Country Status (8)

Country Link
US (3) US6428814B1 (https=)
EP (1) EP1217993B1 (https=)
JP (2) JP4394324B2 (https=)
AT (1) ATE293959T1 (https=)
AU (1) AU7993800A (https=)
CA (1) CA2386782C (https=)
DE (1) DE60019774T2 (https=)
WO (1) WO2001026635A2 (https=)

Families Citing this family (221)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4484247B2 (ja) * 1995-02-24 2010-06-16 エラン ファーマ インターナショナル，リミティド ナノ粒子分散体を含有するエアロゾル
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
MXPA01004381A (es) 1998-11-02 2005-09-08 Elan Corp Plc Composicion de multiparticulado de liberacion modificada.
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US20040057977A1 (en) * 1999-09-22 2004-03-25 Ecolab Inc. Water-based pest bait compositions having water-sensitive insecticides and methods of making and use thereof
JP5698423B2 (ja) 2000-06-27 2015-04-08 ベクトゥラ・リミテッド 医薬組成物で使用するための粒子の製造法
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US7037528B2 (en) 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US7151139B2 (en) * 2001-04-23 2006-12-19 Massachusetts Institute Of Technology Antimicrobial polymeric surfaces
EP1390158A4 (en) * 2001-04-23 2004-06-09 Massachusetts Inst Technology ANTIMICROBIAL POLYMER SURFACES
US9089407B2 (en) 2001-04-23 2015-07-28 Massachusetts Institute Of Technology Antibacterial coatings that inhibit biofilm formation on implants
US6976647B2 (en) * 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
CA2450748A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
CA2456806C (en) 2001-08-08 2011-10-18 Brown University Research Foundation Methods for micronization of hydrophobic drugs
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US20030095928A1 (en) * 2001-09-19 2003-05-22 Elan Pharma International Limited Nanoparticulate insulin
BR0212833A (pt) 2001-09-26 2004-10-13 Baxter Int Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
ES2292848T3 (es) * 2001-10-12 2008-03-16 Elan Pharma International Limited Composiciones que tienen una combinacion de caracteristicas de liberacion inmediata y liberacion controlada.
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
EP1458365A1 (en) * 2001-12-21 2004-09-22 Celator Technologies Inc. Improved polymer-lipid delivery vehicles
EP1471887B1 (en) 2002-02-04 2010-04-21 Elan Pharma International Ltd. Nanoparticulate compositions having lysozyme as a surface stabilizer
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
WO2003080023A2 (en) * 2002-03-20 2003-10-02 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
WO2003080027A1 (en) * 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Nanoparticulate compositions of angiogenesis inhibitors
EP1800666A1 (en) * 2002-03-20 2007-06-27 Elan Pharma International Limited Nanoparticulate compositions of angiogenesis inhibitors
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
EP1494649B1 (en) 2002-04-12 2012-01-04 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
AU2003263024A1 (en) * 2002-04-23 2003-11-10 Christopher Mcconville Process of forming and modifying particles and compositions produced thereby
ATE419835T1 (de) * 2002-05-06 2009-01-15 Elan Pharma Int Ltd Nystatin-nanopartikelzusammensetzungen
US7989503B2 (en) * 2002-05-22 2011-08-02 Nihon Pharmaceutical Co., Ltd. Smooth muscle peristole inhibitor
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
JP4533134B2 (ja) * 2002-06-10 2010-09-01 エラン ファーマ インターナショナル，リミティド ナノ粒子ポリコサノール製剤および新規なポリコサノールの組合せ
EP2283864A1 (en) 2002-07-16 2011-02-16 Elan Pharma International Ltd. Liquid dosage compositions fo stable nanoparticulate active agents
ATE487470T1 (de) * 2002-09-11 2010-11-15 Elan Pharma Int Ltd Gel-stabilisierte wirkstoff-zusammensetzungen in nanoteilchengrösse
EP1556091A1 (en) * 2002-10-04 2005-07-27 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
AU2002346988A1 (en) * 2002-10-10 2004-05-04 Symrise Gmbh And Co. Kg Perfume hair cosmetic composition
CA2504610C (en) * 2002-11-12 2012-02-21 Elan Pharma International Ltd. Fast-disintegrating solid dosage forms being not friable and comprising pullulan
US20050095267A1 (en) * 2002-12-04 2005-05-05 Todd Campbell Nanoparticle-based controlled release polymer coatings for medical implants
WO2004058216A2 (en) * 2002-12-17 2004-07-15 Elan Pharma International Ltd. Milling microgram quantities of nanoparticulate candidate compounds
US7666410B2 (en) 2002-12-20 2010-02-23 Kimberly-Clark Worldwide, Inc. Delivery system for functional compounds
US7582308B2 (en) 2002-12-23 2009-09-01 Kimberly-Clark Worldwide, Inc. Odor control composition
WO2004078162A1 (en) * 2003-01-31 2004-09-16 Elan Pharma International Ltd. Nanoparticulate topiramate formulations
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20040178135A1 (en) * 2003-03-13 2004-09-16 Beplate Douglas K. Filtering device incorporating nanoparticles
WO2004084859A2 (en) 2003-03-21 2004-10-07 Nastech Pharmaceutical Company Inc. Nasal calcitonin formulations containing chlorobutanol
WO2004087307A1 (en) * 2003-03-31 2004-10-14 Boris Olegovich Maier Chitosan product, method for the production thereof, methods for producing chitosan product derivatives and compositions based thereon
EP1626742A1 (en) * 2003-05-22 2006-02-22 Elan Pharma International Limited Sterilization of dispersions of nanoparticulate active agents with gamma radiation
ES2379876T3 (es) * 2003-06-30 2012-05-04 Nihon Pharmaceutical Co., Ltd. Preparación que contiene mentol
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
ATE415946T1 (de) * 2003-08-08 2008-12-15 Elan Pharma Int Ltd Neue metaxalon-zusammensetzungen
RU2006113593A (ru) * 2003-09-23 2006-08-27 Алькон, Инк. (Ch) Препаративные формы триамцинолона ацетонида и анекортава ацетата для инъекций
US7141518B2 (en) 2003-10-16 2006-11-28 Kimberly-Clark Worldwide, Inc. Durable charged particle coatings and materials
US7837663B2 (en) 2003-10-16 2010-11-23 Kimberly-Clark Worldwide, Inc. Odor controlling article including a visual indicating device for monitoring odor absorption
US7488520B2 (en) 2003-10-16 2009-02-10 Kimberly-Clark Worldwide, Inc. High surface area material blends for odor reduction, articles utilizing such blends and methods of using same
US7582485B2 (en) 2003-10-16 2009-09-01 Kimberly-Clark Worldride, Inc. Method and device for detecting ammonia odors and helicobacter pylori urease infection
US7678367B2 (en) 2003-10-16 2010-03-16 Kimberly-Clark Worldwide, Inc. Method for reducing odor using metal-modified particles
US7879350B2 (en) 2003-10-16 2011-02-01 Kimberly-Clark Worldwide, Inc. Method for reducing odor using colloidal nanoparticles
US7794737B2 (en) * 2003-10-16 2010-09-14 Kimberly-Clark Worldwide, Inc. Odor absorbing extrudates
US7438875B2 (en) 2003-10-16 2008-10-21 Kimberly-Clark Worldwide, Inc. Method for reducing odor using metal-modified silica particles
US7413550B2 (en) 2003-10-16 2008-08-19 Kimberly-Clark Worldwide, Inc. Visual indicating device for bad breath
US7754197B2 (en) 2003-10-16 2010-07-13 Kimberly-Clark Worldwide, Inc. Method for reducing odor using coordinated polydentate compounds
EP1686962B9 (en) * 2003-11-05 2012-10-03 Elan Pharma International Limited Nanoparticulate compositions having a peptide as a surface stabilizer
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
JP2007520555A (ja) * 2004-02-05 2007-07-26 バクスター・インターナショナル・インコーポレイテッド 自己安定化剤の使用により調製された分散剤
JP2007533697A (ja) * 2004-04-22 2007-11-22 デュオコート エービー グルココルチコイド救急治療用の医薬組成物
US20050281775A1 (en) * 2004-06-16 2005-12-22 Carrington Stephen D Mucoadhesive and bioadhesive polymers
US20060013873A1 (en) * 2004-07-16 2006-01-19 Chih-Chiang Yang Bioadhesive dosage form of steroids
WO2006083326A2 (en) * 2004-08-07 2006-08-10 Cabot Corporation Gas dispersion manufacture of nanoparticulates and nanoparticulate-containing products and processing thereof
US20060083694A1 (en) 2004-08-07 2006-04-20 Cabot Corporation Multi-component particles comprising inorganic nanoparticles distributed in an organic matrix and processes for making and using same
US8252319B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
SI1814531T1 (sl) 2004-10-21 2010-10-29 Durect Corp Transdermalni dostavni sistem
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
CN101106972A (zh) * 2004-11-16 2008-01-16 伊兰制药国际有限公司 注射用纳米微粒奥氮平制剂
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
WO2006062875A1 (en) * 2004-12-08 2006-06-15 Merck & Co., Inc. Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor
CA2590675A1 (en) * 2004-12-15 2006-06-22 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
WO2006069098A1 (en) * 2004-12-22 2006-06-29 Elan Pharma International Ltd. Nanoparticulate bicalutamide formulations
JP2008527191A (ja) * 2005-01-05 2008-07-24 ダウ グローバル テクノロジーズ インコーポレイティド 紙及び板紙中の殺菌剤の効力の強化
EP1835890A2 (en) * 2005-01-06 2007-09-26 Elan Pharma International Limited Nanoparticulate candesartan formulations
KR20070112164A (ko) 2005-02-15 2007-11-22 엘란 파마 인터내셔널 리미티드 나노입자형 벤조디아제핀의 에어로졸과 주사가능한 제제
ES2490595T3 (es) 2005-02-17 2014-09-04 Abbott Laboratories Administración transmucosal de composiciones de fármacos para tratar y prevenir trastornos en animales
WO2006099121A2 (en) * 2005-03-10 2006-09-21 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride and tamsulosin hydrochloride, and mixtures thereof
US20070065374A1 (en) * 2005-03-16 2007-03-22 Elan Pharma International Limited Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations
BRPI0606280A2 (pt) * 2005-03-17 2009-06-09 Elan Pharma Int Ltd composições de bisfosfonato nanoparticulado
WO2006102494A2 (en) * 2005-03-23 2006-09-28 Elan Pharma International Limited Nanoparticulate corticosteroid and antihistamine formulations
AU2006235487B2 (en) * 2005-04-12 2011-12-22 Elan Pharma International Limited Nanoparticulate quinazoline derivative formulations
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
AU2006235478B2 (en) * 2005-04-12 2011-07-21 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cyclosporine
US20110064803A1 (en) * 2005-05-10 2011-03-17 Elan Pharma International Limited. Nanoparticulate and controlled release compositions comprising vitamin k2
JP2008540546A (ja) * 2005-05-10 2008-11-20 エラン ファーマ インターナショナル リミテッド ナノ粒子クロピドグレル製剤
US20060286239A1 (en) * 2005-05-20 2006-12-21 Philip Morris Usa Inc. Nanoscale materials
CN101262860A (zh) * 2005-06-03 2008-09-10 伊兰制药国际有限公司 纳米微粒对乙酰氨基酚制剂
EA015102B1 (ru) * 2005-06-03 2011-06-30 Элан Фарма Интернэшнл Лтд. Препараты наночастиц мезилата иматиниба
WO2006133045A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate benidipine compositions
WO2008073068A1 (en) 2005-06-08 2008-06-19 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cefditoren
ES2335608T3 (es) * 2005-06-09 2010-03-30 Elan Pharma International Limited Formulaciones de ebistina nanoparticuladas.
MX2007015882A (es) * 2005-06-13 2008-03-04 Elan Pharma Int Ltd Formulaciones en combinacion nanoparticulada de clopidogrel y aspirina.
CA2612384A1 (en) * 2005-06-15 2006-12-28 Elan Pharma International, Limited Nanoparticulate azelnidipine formulations
JP2009500356A (ja) * 2005-07-07 2009-01-08 エラン ファーマ インターナショナル リミテッド ナノ粒子クラリスロマイシン製剤
JP2009507925A (ja) * 2005-09-13 2009-02-26 エラン ファーマ インターナショナル リミテッド ナノ粒子タダラフィル製剤
CA2622758A1 (en) * 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
US20080249136A1 (en) * 2005-10-25 2008-10-09 Ioana Annis Antimicrobial Composition and Method
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) * 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US7858609B2 (en) * 2005-11-28 2010-12-28 Marinus Pharmaceuticals Solid ganaxolone formulations and methods for the making and use thereof
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
CA2648099C (en) 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
US7977103B2 (en) 2006-04-20 2011-07-12 Kimberly-Clark Worldwide, Inc. Method for detecting the onset of ovulation
JP5630998B2 (ja) 2006-05-15 2014-11-26 マサチューセッツ インスティテュート オブ テクノロジー 機能的粒子のためのポリマー
SG170047A1 (en) * 2006-05-30 2011-04-29 Elan Pharma Int Ltd Nanoparticulate posaconazole formulations
WO2007146319A2 (en) * 2006-06-13 2007-12-21 Symphony Medical, Inc. Methods and apparatus for using polymer-based beads and hydrogels for cardiac applications
WO2007150030A2 (en) * 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
AU2007264418B2 (en) 2006-06-30 2012-05-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
JP2009543797A (ja) * 2006-07-10 2009-12-10 エラン ファーマ インターナショナル，リミティド ナノ粒子ソラフェニブ製剤
AU2007272501A1 (en) * 2006-07-12 2008-01-17 Elan Pharma International Limited Nanoparticulate formulations of modafinil
WO2008019142A2 (en) * 2006-08-04 2008-02-14 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
WO2008127416A2 (en) * 2006-11-08 2008-10-23 Massachusetts Institute Of Technology Polymeric coatings that inactivate viruses and bacteria
BRPI0717721A2 (pt) 2006-11-28 2013-10-29 Marinus Pharmaceuticals "partículas complexadas de drogas, composição farmacêutica, uso de uma composição farmacêutica, partículas complexadas de droga estabilizadas no tamanho, método para a preparação de partículas estabilizadas da droga, composição farmacêutica sólida, comprimido oral ingerível e composição líquida em nanopartículas estabilizadas no tamanho"
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
EP2134830A2 (en) 2007-02-09 2009-12-23 Massachusetts Institute of Technology Oscillating cell culture bioreactor
WO2008118754A2 (en) * 2007-03-23 2008-10-02 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods for making the same
WO2008124634A1 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
JP2010523595A (ja) * 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ（アミノ酸）ターゲッティング部分
WO2008125940A2 (en) * 2007-04-17 2008-10-23 Pfizer Products Inc. Nanoparticles comprising non-crystalline drug
US20080268140A1 (en) 2007-04-26 2008-10-30 Csd, Inc. Temporary removable solvent based protective coating
US8221574B2 (en) 2007-04-26 2012-07-17 Csd, Llc Top coating for indoor and outdoor temporary removable graphics and system and method for making, applying and removing such graphics
US8703204B2 (en) 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US8309129B2 (en) 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135852A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles and casein
EP2152274A4 (en) * 2007-05-07 2010-07-21 Questor Pharmaceuticals Inc NASAL ADMINISTRATION OF BENZODIAZEPINES
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
EP2162120B1 (en) 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
GB0714223D0 (en) * 2007-07-20 2007-08-29 Fujifilm Mfg Europe Bv Preparation of fine particles
JP5453260B2 (ja) * 2007-07-25 2014-03-26 スリーエム イノベイティブ プロパティズ カンパニー 被膜形成歯科用組成物及び関連する方法
EP2180873B1 (en) 2007-07-25 2018-04-11 3M Innovative Properties Company Therapeutic dental composition for use in the inhibition of biofilm formation in the oral cavity.
JP2011500569A (ja) 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー ワクチンナノテクノロジー
CN101969956B (zh) * 2007-11-13 2014-03-05 梅里蒂奇制药公司 皮质类固醇组合物
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US8865692B2 (en) * 2007-11-13 2014-10-21 Meritage Pharma, Inc Compositions for the treatment of gastrointestinal inflammation
US20090149433A1 (en) 2007-11-13 2009-06-11 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090148491A1 (en) * 2007-12-05 2009-06-11 Abbott Cardiovascular Systems Inc. Dual-Targeted Drug Carriers
EP2231169B1 (en) 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
WO2009073216A1 (en) 2007-12-06 2009-06-11 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
AU2009225719A1 (en) * 2008-03-21 2009-09-24 Elan Pharma International Limited Compositions for site-specific delivery of imatinib and methods of use
US20090258865A1 (en) 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
WO2009130704A1 (en) * 2008-04-24 2009-10-29 Technion Research And Development Foundation Ltd. Beta-lactoglobulin-polysaccharide nanoparticles for hydrophobic bioactive compounds
AU2009256194A1 (en) * 2008-06-06 2009-12-10 Avery Dennison Corporation Temporary outdoor graphic film
TWI580441B (zh) * 2008-09-19 2017-05-01 愛爾康研究有限公司 穩定的藥學次微米懸浮液及其形成方法
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
WO2010099508A1 (en) 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
CN102438594A (zh) 2009-04-24 2012-05-02 伊休蒂卡有限公司 吲哚美辛的新剂型
FR2945950A1 (fr) 2009-05-27 2010-12-03 Elan Pharma Int Ltd Compositions de nanoparticules anticancereuses et procedes pour les preparer
EP3167875A1 (en) 2009-05-27 2017-05-17 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate meloxicam compositions
EP2442786A1 (en) 2009-06-15 2012-04-25 Chemyunion Química Ltda Sericin cationic nanoparticles for application in products for hair and dyed hair
AU2010261510A1 (en) 2009-06-19 2012-02-09 Nanoform Hungary Ltd. Nanostructured Sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
UA109772C2 (uk) * 2009-07-02 2015-10-12 Агент для підвищення гідрофільності ґрунту і способи його застосування
KR20130020742A (ko) * 2010-02-07 2013-02-27 제이.피.엠.이.디. 리미티드 모낭 표적 조성물
WO2011146583A2 (en) 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet formulations
GB201011905D0 (en) * 2010-07-15 2010-09-01 Unilever Plc Benefit delivery particle,process for preparing said particle,compositions comprising said particles and a method for treating substrates
US9005664B2 (en) * 2010-10-17 2015-04-14 Technion Research And Development Foundation Ltd. Denatured lactoglobulin and polyphenol coassemblies
WO2012149326A1 (en) 2011-04-29 2012-11-01 Massachusetts Institute Of Technology Layer processing for pharmaceuticals
ES2683902T3 (es) 2011-06-14 2018-09-28 Hale Biopharma Ventures, Llc Administración de benzodiacepina
DK2785310T3 (da) 2011-11-30 2018-01-29 Institució Catalana De Recerca I Estudis Avançats Fremgangsmåde til øget fotoepilering baseret på metalliske nanopartikler.
US9408419B2 (en) 2012-03-23 2016-08-09 Victoria's Secret Store Brand Management, Inc. Moisturizing fabric material, use thereof in moisturizing bras, and method of manufacture
WO2013165604A1 (en) * 2012-05-02 2013-11-07 Massachusetts Institute Of Technology Electroprocessing of active pharmaceutical ingredients
US9334200B2 (en) 2013-01-28 2016-05-10 Bfp Management, Llc Fertilizer composition and method for suspending fertilizer in an aqueous solution
AU2014248455B2 (en) 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
JP2015209380A (ja) 2014-04-24 2015-11-24 ロレアル 化粧用組成物
US10213960B2 (en) 2014-05-20 2019-02-26 Massachusetts Institute Of Technology Plasticity induced bonding
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
CA2984421C (en) 2015-05-01 2024-04-09 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
WO2017070578A1 (en) 2015-10-21 2017-04-27 The Regents Of The University Of Michigan Detection and treatment of caries and microcavities with nanoparticles
EP3481387A4 (en) 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
WO2019018664A1 (en) * 2017-07-19 2019-01-24 Dentsply Sirona Inc. HYDROSOLUBLE HYDROGEL BASED DENTAL COMPOSITION AND METHODS OF MAKING AND USING SAME
CN111971284A (zh) 2017-12-27 2020-11-20 埃默里大学 核苷和/或nadph氧化酶(nox)抑制剂作为髓样特异性抗病毒剂的联合模式
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
BR112021024310A2 (pt) 2019-06-05 2022-02-15 Univ Emory Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus
JP7754799B2 (ja) 2019-08-05 2025-10-15 マリナス ファーマシューティカルズ， インコーポレイテッド てんかん重積状態の治療に使用するためのガナキソロン
KR20220126286A (ko) 2019-11-01 2022-09-15 어퀘스티브 테라퓨틱스, 아이엔씨. 전구약물 조성물 및 치료 방법
KR20220126287A (ko) 2019-11-14 2022-09-15 어퀘스티브 테라퓨틱스, 아이엔씨. 멀티모달 조성물 및 치료 방법
WO2021113834A1 (en) 2019-12-06 2021-06-10 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
EP4277611A1 (en) 2021-01-15 2023-11-22 Aquestive Therapeutics, Inc. Prodrug compositions and methods of treatment
JP2024521399A (ja) 2021-06-10 2024-05-31 ニューレリス、インク． 小児患者における発作性障害を治療するための組成物および方法
US12391640B2 (en) 2022-03-02 2025-08-19 Horizon Therapeutics Ireland Dac Process of making a crystalline EDG-2 receptor antagonist

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3013839A1 (de) 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
ZA822995B (en) 1981-05-21 1983-12-28 Wyeth John & Brother Ltd Slow release pharmaceutical composition
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4757059A (en) 1984-08-14 1988-07-12 International Copper Research Association Method for treating convulsions and epilepsy with organic copper compounds
CA1264566A (en) 1984-09-05 1990-01-23 Tetsuji Iwasaki Biocidal fine powder, its manufacturing method and a suspension for agricultural use containing the above powder
US4783484A (en) 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
US4727077A (en) 1985-02-20 1988-02-23 Ishihara Sangyo Kaisha Ltd. Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
JPS62185013A (ja) 1986-02-08 1987-08-13 Green Cross Corp:The 易吸収性医薬組成物
DE3620685A1 (de) 1986-06-20 1987-12-23 Henkel Kgaa Neue mittel zur abdeckung unverletzter und/oder verletzter bereiche menschlicher oder tierischer haut
EP0262560A3 (en) 1986-09-29 1989-07-05 Ishihara Sangyo Kaisha, Ltd. Benzoyl urea compound
US4983605A (en) 1986-10-23 1991-01-08 Ishihara Sangyo Kaisha Ltd. Pharmaceutical composition
FR2634397B2 (fr) 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
FR2608942B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules
FR2608988B1 (fr) 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
DE3883918T2 (de) 1987-11-03 1994-01-20 Ilford Ltd Vorrichtung zur Herstellung geänderter Abdrucke.
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
JP2661709B2 (ja) 1988-07-08 1997-10-08 ダウ・ケミカル日本株式会社 高活性な農薬水和剤の製法
ES2052016T3 (es) * 1988-09-29 1994-07-01 Shiseido Co Ltd Composicion emulsionada.
JPH02196719A (ja) 1989-01-24 1990-08-03 Green Cross Corp:The 粉末状医薬組成物
US5750134A (en) * 1989-11-03 1998-05-12 Riker Laboratories, Inc. Bioadhesive composition and patch
AU7077091A (en) 1990-01-11 1991-08-05 E.I. Du Pont De Nemours And Company Herbicidal pyrimidines and triazines
US5156767A (en) 1990-01-16 1992-10-20 Conoco Inc. Emulsion breaking using alkylphenol-polyethylene oxide-acrylate polymer coated coalescer material
HU212435B (en) 1990-06-07 1996-06-28 Sandoz Ag Herbicidal compositions containing substituted phthalides and heterocyclic phthalides as active ingredient and process for preparation of their active ingredients.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5766635A (en) 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
CA2112905A1 (en) 1991-07-05 1993-01-21 Michael R. Violante Ultrasmall non-aggregated porous particles entrapping gas-bubbles
HU9203730D0 (en) 1991-12-06 1993-03-29 Sandoz Ag Substituted phthalides and heterocyclic ones
JPH07112936A (ja) 1992-04-27 1995-05-02 Philippe Perovich 治療用成分、とくにアスピリンに基づく成分の製剤方法
DE69309098T3 (de) 1992-11-16 2002-03-07 The Procter & Gamble Company, Cincinnati Gewebeweichspülzusammensetzungen mit farbstofftransferinhibitoren zwecks verbessertem gewebeerscheinungsbild
DE69327542T2 (de) 1992-11-17 2000-07-06 Yoshitomi Pharmaceutical Industries, Ltd. Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung
AU660852B2 (en) 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
FR2698560B1 (fr) 1992-11-30 1995-02-03 Virbac Laboratoires Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5326552A (en) 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
DE4324396A1 (de) 1993-07-21 1995-01-26 Henkel Kgaa Reinigungsmittel mit hohem Benetzungsvermögen
US6177104B1 (en) 1994-01-27 2001-01-23 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving dosage form
US5912219A (en) 1994-02-03 1999-06-15 The Procter & Gamble Company Acidic cleaning compositions
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
BE1008307A3 (fr) 1994-06-16 1996-04-02 Europharmaceuticals Sa Sel de nimesulide hydrosoluble, solution aqueuse le contenant, sa preparation et son utilisation.
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5707981A (en) 1994-07-28 1998-01-13 Psorial, L.L.C. Synergistic pharmaceutical compositions
CZ285638B6 (cs) 1994-10-07 1999-10-13 Eka Chemicals Ab Částice obsahující peroxysloučeninu a prostředek, který je obsahuje
US5935271A (en) 1994-10-13 1999-08-10 Procter & Gamble Company Laundry detergent compositions containing lipolytic enzyme and amines
US5466440A (en) * 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5853756A (en) 1995-01-11 1998-12-29 J. B. Chemicals & Pharmaceuticals Limited Controlled release formulations of Ranitidine
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5503723A (en) 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5593657A (en) 1995-02-09 1997-01-14 Nanosystems L.L.C. Barium salt formulations stabilized by non-ionic and anionic stabilizers
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5632996A (en) 1995-04-14 1997-05-27 Imaginative Research Associates, Inc. Benzoyl peroxide and benzoate ester containing compositions suitable for contact with skin
US6316022B1 (en) * 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
EP0844993B1 (en) 1995-08-15 2007-09-26 Bayer CropScience AG Pesticidal indazole derivatives
US5827822A (en) 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5932535A (en) 1995-12-21 1999-08-03 Henkel Kommanditgesellschaft Auf Aktien Process for the production of light-colored, low-viscosity surfactant concentrates
CA2232152C (en) 1995-12-27 2007-02-06 Janssen Pharmaceutica N.V. Bioadhesive solid dosage form
JP4107693B2 (ja) 1996-02-09 2008-06-25 保土谷化学工業株式会社 固体粒子水性懸濁液の製造方法
KR970061942A (ko) 1996-02-09 1997-09-12 무또 미노루 복합 입자 수성 현탁액 및 이의 제조 방법
US5932202A (en) 1996-03-27 1999-08-03 The Procter & Gamble Company Conditioning shampoo composition
US5935561A (en) 1996-03-27 1999-08-10 Procter & Gamble Company Conditioning shampoo compositions containing select hair conditioning agents
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
CZ402198A3 (cs) 1996-06-07 1999-05-12 Hercules Incorporated Zubní pasta obsahující fluidizovanou polymerní suspenzi karboxymethylcelulózy
DE59709127D1 (de) 1996-07-08 2003-02-20 Ciba Sc Holding Ag Triazinderivate als UV-Filter in Sonnenschutzmitteln
KR100360522B1 (ko) 1996-07-25 2002-11-13 니키 유니바사루 가부시키가이샤 공기 정화 필터
WO1998007414A1 (en) 1996-08-22 1998-02-26 Research Triangle Pharmaceuticals Ltd. Compositions comprising microparticles of water-insoluble substances and method for preparing same
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US5932404A (en) 1996-12-18 1999-08-03 Eastman Kodak Company Silver halide photographic material containing a polymer with a photographically useful group which is rendered non-diffusible by cross-linking
JPH10194996A (ja) 1996-12-25 1998-07-28 Janssen Pharmaceut Nv アシル化シクロデキストリン含有製薬組成物
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
FR2758461A1 (fr) 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
GB9703552D0 (en) 1997-02-20 1997-04-09 Dow Corning Polymerisation of cyclosiloxanes in the presence of fillers
US20050004049A1 (en) 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
US5891420A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
CA2261787C (en) 1997-05-30 2006-11-14 Laboratorios Phoenix U.S.A., Inc. Multi-layered osmotic device
IE970731A1 (en) 1997-10-07 2000-10-04 Fuisz Internat Ltd Product and method for the treatment of hyperlipidemia
US5929024A (en) 1997-11-20 1999-07-27 Colgate Palmolive Company Cleaning compositions
US5938017A (en) * 1998-05-04 1999-08-17 Wik; Dennis O. Article for assisting persons to quit smoking and method for same
IL140276A0 (en) * 1998-06-19 2002-02-10 Rtp Pharma Inc Processes to generate submicron particles of water-insoluble compounds
EP2266542A3 (en) 1998-10-01 2013-07-31 Elan Pharma International Limited Controlled release nanoparticulate compositions
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US5935921A (en) 1999-01-26 1999-08-10 Colgate-Palmolive Co. Liquid descaling composition
US5935272A (en) 1999-02-02 1999-08-10 Milliken & Company Compositions comprising aryloxypolyoxyalkylene naphthalimide derivative colorants
US6267989B1 (en) 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
ES2367352T3 (es) 1999-04-28 2011-11-02 Genetics Institute, Llc Tratamiento de la fibrosis meidante el antagonismo de la il-3 y de las cadenas del receptor del il-3.
US6656504B1 (en) 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
KR100364496B1 (ko) * 2000-07-14 2002-12-12 에쓰대시오일 주식회사 마이크로파를 이용한 폴리카보네이트 수지의 제조방법
JP4223390B2 (ja) 2001-06-05 2009-02-12 エラン・ファルマ・インターナショナル・リミテッド 材料をフライス削りするシステムおよび方法
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
JP4502318B2 (ja) 2004-06-02 2010-07-14 河村電器産業株式会社 漏電遮断器

Also Published As

Publication number Publication date
CA2386782C (en) 2009-12-15
JP4394324B2 (ja) 2010-01-06
CA2386782A1 (en) 2001-04-19
EP1217993B1 (en) 2005-04-27
WO2001026635A3 (en) 2001-09-13
WO2001026635A2 (en) 2001-04-19
US6428814B1 (en) 2002-08-06
JP2010018604A (ja) 2010-01-28
AU7993800A (en) 2001-04-23
US20080003295A1 (en) 2008-01-03
EP1217993A2 (en) 2002-07-03
US20030108611A1 (en) 2003-06-12
ATE293959T1 (de) 2005-05-15
JP2003511406A (ja) 2003-03-25
US20020068092A1 (en) 2002-06-06
US7288267B2 (en) 2007-10-30
US7850995B2 (en) 2010-12-14
DE60019774D1 (de) 2005-06-02

Similar Documents

Publication Publication Date Title
DE60019774T2 (de) Bioadhäsive nanopartikelformulierungen mit kationischen oberflächenstabilisatoren
JP4598399B2 (ja) 表面安定剤としてリゾチームを有するナノ粒子組成物
DE69826256T3 (de) Verfahren zur erhöhung der haftung eines produktes auf einer oberfläche
DE60224365T2 (de) System mit kontrollierter abgabe für haarpflegemittel
DE69933208T2 (de) Verwendung von zusammensetzungen mit antiseptika und/oder die wundheilung fördernden wirkstoffen für den tieferen atemwegstrakt
DE60020732T2 (de) Verfahren zur herstellung von nanometer partikeln durch fliessbett- sprühtrocknung
DE69830542T2 (de) Verwendung von speziellen Polyaminpolymeren als Antioxidantien
DE69628640T2 (de) Polyalkylen-block-copolymere als oberflächenmodifikatoren für nanopartikel
DE69424288T2 (de) Partikel mit modifizierten physikalisch-chemischen eigenschaften, ihre herstellung und verwendung
WO2003032959A1 (en) Nanoparticulate compositions comprising inorganic cores
EP1072259B1 (en) Microcapsule and method of making the same
DE68928034T2 (de) Protein mit zeitverabreichung
US6500446B1 (en) Compositions which contain at least one cationic polymer and at least one active molecule contained in at least one micro or nonopartculate vector, and their use for treating living or inert surfaces
EP1176949A2 (de) Lipidpartikel auf der basis von mischungen von flüssigen und festen lipiden und verfahren zu ihrer herstellung
DE19916896A1 (de) Teilchen mit kleiner Dimension, die eine Wand aus einem Gemisch von vernetzten Proteinen und Polysacchariden aufweisen, die an der Oberfläche mit Metallionen cheltbildende Hydroxamgruppen enthalten, Verfahren zu ihrer Herstellung und ihre verschiedenen Verwendungen insbesondere in der kosmetischen, pharmazeutischen und Nahrungsmittelindustrie
EP0799021A1 (de) Kosmetische kaolinhaltige zubereitung
DE60018409T2 (de) Verwendung von antiseptika zur herstelllung von arzneimitteln zur prophylaxe und behandlung von infektionen und/ oder funktionellen gewebeumformungen im körperinneren
Saif et al. Improving the bioavailability of three-dimensional ZIF-8 MOFs against carbon tetrachloride-induced brain and spleen toxicity in rats
DE69008117T2 (de) Endermaler Arzneistoff in einer Gelbasis.
EP1940972A2 (de) Zweischichtig oberflächenmodifiziertes nanopartikuläres zinkoxid, verfahren zu dessen herstellung und verwendung desselben
Purkait et al. International Journal of Green and Herbal Chemistry

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: DF-MP, 80333 MUENCHEN